News >

Expert Discusses Potential Breakthroughs in ROS1+ and BRAF+ NSCLC

Angelica Welch
Published: Monday, Jun 25, 2018

Dr. Sai-Hong Ignatius Ou

Sai-Hong Ignatius Ou, MD, PhD

The treatment of patients with non–small cell lung cancer (NSCLC) was revolutionized with the discovery of targetable mutations more than a decade ago. Although many agents have been approved in the ALK-positive NSCLC landscape since then, other targets, such as ROS1 and BRAF, are under investigation in a new age of targeted therapies, said Sai-Hong Ignatius Ou, MD, PhD.

alterations. Although it is a 23-gene panel, it can only be used to test for these 3 alterations, based on the FDA’s indication, explained Ou.

ROS1-Rearranged NSCLC

The ROS1-rearrangement was discovered in lung cancer around the same time as ALK in 2007. This receptor tyrosine kinase fusion is also seen in other tumor types such as brain, breast, soft tissue, skin, stomach, and ovarian cancer. All receptor tyrosine kinase fusions have fusion partners, said Ou, adding that there are about 13 fusions partners established for ROS1.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication